Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting

• Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift System vs. other modalities to treat benign prostatic hyperplasia (BPH) -
• Additional studies examine post-surgery medication use, rates of hospitalization and adverse events of standard BPH treatments -
  
• Teleflex unveils latest advancements in BPH treatment with UroLift 2 System with Advanced Tissue Control (ATC) designed to treat all prostate types -
  

WAYNE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies, today announced the presentation of multiple clinical studies at the 2024 American Urological Association Annual Meeting, which is being held in San Antonio, TX, from May 3 – 6, 2024. These studies add to the growing body of clinical evidence around the safety, efficacy and patient experience* with a Prostatic Urethral Lift (PUL) using the UroLift System for benign BPH.

In addition to the presentation of clinical data, Teleflex will offer the first opportunity to view the UroLift 2 System with Advanced Tissue Control (ATC), which has recently received FDA clearance. The UroLift 2 ATC System offers physicians enhanced confidence, easier control of obstructive tissue, and targeting accuracy through tissue control wings and laser-etched needle markers designed to make tissue manipulation and implant delivery more precise.¹ A streamlined delivery system, utilizing typically one handle per procedure and individual implant cartridges, promotes increased physician comfort and improved efficiency during the procedure.¹

BPH is a common condition in which the prostate enlarges as men get older. The enlarged prostate can press on and block the urethra, causing bothersome urinary symptoms. The UroLift System is a minimally invasive treatment option for BPH that can help men get off BPH medications and avoid major surgery, while preserving sexual function.²** It is the only leading enlarged prostate procedure that does not require heating, cutting or destruction of prostate tissue.^3,4

“Assessing the comparative safety and effectiveness of leading therapeutic modalities through clinical trials is paramount in optimizing patient-centered care for benign prostatic hyperplasia,” said Liam Kelly, Chairman, President and CEO of Teleflex. “It’s also critical to understand how these therapies perform in real-world settings and reflect patient experience. Teleflex has always made a strong commitment to generating both clinical and real-world evidence that supports and optimizes the use of the UroLift procedure to improve patient outcomes.”